Viravaxx

Landmark paper on Viravaxx’ rhinovirus diagnostic tool published in Nature Communications

Viravaxx announced today that a Landmark paper describing the utility of its multiplexed diagnostic chip for analysis of the immune response to a rhinovirus infection in children has been published in the high impact Journal Nature Communications. The following is a comment in the “behind the paper” blog in Nature Community Microbiology: “Major factors triggering asthma attacks | read more »

Viravaxx announced today that a Landmark paper describing the utility of its multiplexed diagnostic chip for analysis of the immune response to a rhinovirus infection in children has been published in the high impact Journal Nature Communications. The following is a comment in the “behind the paper” blog in Nature Community Microbiology:

“Major factors triggering asthma attacks are allergens and infections by rhinovirus, the cause of common cold. Whether an asthma attack is really caused by a rhinovirus infection could not be firmly established so far because only nucleic-acid based strategies for virus detection have been available but no serological tests measuring rhinovirus-specific immune responses. We developed the “PreDicta” chip which contains a large collection of micro-arrayed peptides and proteins representing the currently known rhinovirus species and strains. Our study shows that one can identify the culprit rhinovirus species in children with wheeze attacks by measuring strain-specific increases of antibodies with only a drop of blood. We could not only identify the culprit virus species having caused the wheeze attacks but our data also indicate that certain species are especially dangerous. Using the rhinovirus chip many important open questions can be answered. For example, it can now be studied if rhinovirus infections trigger also exacerbations of other respiratory diseases such as chronic obstructive pulmonary disease (COPD). The worldwide analysis of rhinovirus infections as triggers for respiratory disease attacks with the high resolution chip will also identify the clinically most relevant rhinovirus strains for the rational engineering of a vaccine for rhinovirus infections, a much after sought goal in vaccinology. Another unanswered question which can be addressed with the chip is: Will it be possible to predict the course of a respiratory disease based on RV-specific antibody levels measured at certain time points or age? We think yes, because many longitudinal population cohorts have been established in which clinical data and serum samples have been collected and can now be analyzed with our chip.”

Rainer Henning, CEO of Viravaxx, commented: “The publication of this important paper provides testament to the very relevant work that Viravaxx is performing in collaboration with important research institutions  like the Medical University in Vienna and the Karolinska Institute. We are now in the process of setting up and validating the manufacturing proces for this device. We predict that we will be able to commercialize this product for the research market early next year. We have already registered very significant demand from research groups following large longitudinal population cohorts.”